Centchroman
Alternative Name: Saheli; Ormeloxifene
Description: A non-hormonal oral contraceptive available only in India. It is a selective estrogen receptor modulator (SERM). It is also used for management of abnormal uterine bleeding (AUB) and as an emergency contraceptive, in addition to use as a weekly contraceptive.
Product Details
User: Female
Hormonal: No
Delivery Method: Oral
Duration Type: Short-acting, Emergency
Duration: One week
Regimen: - weekly
- weekly
Dose: 30 mg
Active Pharmaceutical Ingredient (API): - ormeloxifene
- ormeloxifene
Multipurpose Preventive Technology (MPT): No
Status Details
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Project Phase: Limited Market Availability
Development Stage: Marketed
Began discovery in: 1977
Active Development: Yes
Status Details: - Centchroman has been in use as a weekly oral contraceptive in India for nearly 20 years.
- In one trial centchroman was shown to induce apoptosis in human breast cancer cells. Clinical research activities underway to develop this product for management of osteoporosis and advanced breast cancer.
- Centchroman has been in use as a weekly oral contraceptive in India for nearly 20 years.
- In one trial centchroman was shown to induce apoptosis in human breast cancer cells. Clinical research activities underway to develop this product for management of osteoporosis and advanced breast cancer.
Additional Information
References: HLL website: http://www.lifecarehll.com/product/view/reference/698d51a19d8a121ce58149...
Singh MM. (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 21(4): 302-47.
Kamboj VP, Ray S, Anand N. Centchroman: a safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front BioSci. 2018 Jan 1; 10:1-14.
Dewangan J, Kaushik S, Rath SK, Balapure AK. Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1a/VEGFR signaling axis. LifeSci 2018 Jan 15. 193:9-19.
HLL website: http://www.lifecarehll.com/product/view/reference/698d51a19d8a121ce58149...
Singh MM. (2001) Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 21(4): 302-47.
Kamboj VP, Ray S, Anand N. Centchroman: a safe reversible postcoital contraceptive with curative and prophylactic activity in many disorders. Front BioSci. 2018 Jan 1; 10:1-14.
Dewangan J, Kaushik S, Rath SK, Balapure AK. Centchroman regulates breast cancer angiogenesis via inhibition of HIF-1a/VEGFR signaling axis. LifeSci 2018 Jan 15. 193:9-19.